Lates News

Regenxbio (RGNX.US): In the third quarter of 2025, the revenue reached 29.733 million US dollars, up from 24.197 million US dollars in the previous period, and higher than the expected value of 24.2552 million US dollars. Earnings per share were -1.20 US dollars, compared to -1.17 US dollars in the previous period, and better than the expected value of -1.33 US dollars.